Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Подходы к диагностике и терапии меланомы кожи: эра персонализированной медицины
Подходы к диагностике и терапии меланомы кожи: эра персонализированной медицины
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Полный текст
Список литературы
1. World Health Organization. Skin cancers. Available from www.who.int (last accessed September 15, 2011).
2. Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France. Intl Ag Res Can 2010.
3. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). М.: Изд-во МНИОИ им. П.А. Герцена, 2012.
4. Lotze MT, Dallal RM, Kirkwood JM, Flickinger JC. Cutaneous melanoma. In De Vita VT, Rosenberg SA, Hellman S. (eds.), Principles and Practice of Oncology, 6 th ed. Philadelphia: Lippincott, 2001.
5. Bleyer A, O’Leary M, Barr R, Ries LAG. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975–2000.
6. Bethesda MD. National Cancer Institute; 2006. American Cancer Society. Can Fact Figur 2013. http://www.cancer.org/acs/groups/
content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Accessed January 31, 2013.
7. Australian Institute of Health and Welfare and Australasian Association of Cancer Registries (2008). Cancer in Australia: an overview, 2008. AIHW cat. no. CAN 32.
8. AIHW 2012. Cancer in Australia 2012: an overview. Cancer series no. 74. Cat. no. CAN 70. Canberra: AIHW.
9. Balch CM, Gershenwald JE, Soong SJ et al. Final Version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol 27: p. 6199–206.
10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology TM Melanoma 2013; 2.
11. Демидов Л.В., Утяшев И.А. Хирургическое лечение меланомы кожи. Практическая онкология. 2012; 13 (2): 125–34.
12. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Nat Can Ins 2010; 102: 493–501.
13. Харкевич Г.Ю., Демидов Л.В. Современный взгляд на лекарственное лечение диссеминированной меланомы кожи. Практические рекомендации общества онкологов-химиотерапевтов по диагностике, лечению и наблюдению больных меланомой кожи. Версия 2012 г. Практическая онкология. 2012; 13 (2).
14.Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23. [Erratum, N Engl J Med 2010; 363: 1290]
15. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517–26.
16. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–54.
17.Omholt K, Platz A, Kanter L et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clinical Cancer Research 2003; 9: 6483–8.
18. Mandalà M, Voit C. Targeting BRAF in melanoma: Biological and clinical challenges. Crit Rev Oncol Hematol 2013 Feb 14. pii: S1040-8428(13)00029-2.
19. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809–19.
20. Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366 (8): 707–14.
21. Paul B. Chapman, Axel Hauschild, Caroline Robert et al. Updatedoverall survival (OS) results for BRIM-3, a phase III randomized, openlabel, multicenter trial comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 2012; 30 (Suppl; abstr 8502).
22. www.clinicaltrials.gov
2. Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France. Intl Ag Res Can 2010.
3. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). М.: Изд-во МНИОИ им. П.А. Герцена, 2012.
4. Lotze MT, Dallal RM, Kirkwood JM, Flickinger JC. Cutaneous melanoma. In De Vita VT, Rosenberg SA, Hellman S. (eds.), Principles and Practice of Oncology, 6 th ed. Philadelphia: Lippincott, 2001.
5. Bleyer A, O’Leary M, Barr R, Ries LAG. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975–2000.
6. Bethesda MD. National Cancer Institute; 2006. American Cancer Society. Can Fact Figur 2013. http://www.cancer.org/acs/groups/
content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Accessed January 31, 2013.
7. Australian Institute of Health and Welfare and Australasian Association of Cancer Registries (2008). Cancer in Australia: an overview, 2008. AIHW cat. no. CAN 32.
8. AIHW 2012. Cancer in Australia 2012: an overview. Cancer series no. 74. Cat. no. CAN 70. Canberra: AIHW.
9. Balch CM, Gershenwald JE, Soong SJ et al. Final Version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol 27: p. 6199–206.
10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology TM Melanoma 2013; 2.
11. Демидов Л.В., Утяшев И.А. Хирургическое лечение меланомы кожи. Практическая онкология. 2012; 13 (2): 125–34.
12. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Nat Can Ins 2010; 102: 493–501.
13. Харкевич Г.Ю., Демидов Л.В. Современный взгляд на лекарственное лечение диссеминированной меланомы кожи. Практические рекомендации общества онкологов-химиотерапевтов по диагностике, лечению и наблюдению больных меланомой кожи. Версия 2012 г. Практическая онкология. 2012; 13 (2).
14.Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23. [Erratum, N Engl J Med 2010; 363: 1290]
15. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517–26.
16. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–54.
17.Omholt K, Platz A, Kanter L et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clinical Cancer Research 2003; 9: 6483–8.
18. Mandalà M, Voit C. Targeting BRAF in melanoma: Biological and clinical challenges. Crit Rev Oncol Hematol 2013 Feb 14. pii: S1040-8428(13)00029-2.
19. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809–19.
20. Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366 (8): 707–14.
21. Paul B. Chapman, Axel Hauschild, Caroline Robert et al. Updatedoverall survival (OS) results for BRIM-3, a phase III randomized, openlabel, multicenter trial comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 2012; 30 (Suppl; abstr 8502).
22. www.clinicaltrials.gov
Авторы
Л.В.Демидов, И.А.Утяшев, Г.Ю.Харкевич
ФГБУ РОНЦ им. Н.Н.Блохина РАМН, Москва
ФГБУ РОНЦ им. Н.Н.Блохина РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.